Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study

• Published in: Kanzo Vol. 65; no. 8; pp. 368 - 390
• Main Authors: Tsutsumi, Takeya, Yotsuyanagi, Hiroshi
• Format: Journal Article
• Language: Japanese
• Published: The Japan Society of Hepatology 01.08.2024
• Subjects: chronic hepatitis C; comorbidities; direct-acting antiviral; drug-drug interactions; Japan
• ISSN: 0451-4203; 1881-3593
• DOI: 10.2957/kanzo.65.368

Direct-acting antivirals (DAAs) can improve outcomes for chronic hepatitis C (CHC) patients. However, they are vulnerable to drug- drug interactions (DDIs), especially patients with other medical conditions. Utilizing data from the Medical Data Vision database, we examined the prevalence of comorbidities and potential DDIs between comedications and DAA regimens in CHC patients in Japan. Of 173,796 patients identified (mean age = 69.0 years), 37.2% had stage F3-4 fibrosis and 11.3% had received ≥1 DAA regimen. Most patients (84.4%) had ≥1 comorbidity, with the mean number of comorbidities per patient increasing with age. Potential contraindicated DDIs in DAA-untreated patients were least likely to occur with elbasvir (EBR) +grazoprevir (GZR) (1.6%) and sofosbuvir (SOF)/velpatasvir (VEL) (1.7%) and most likely with paritaprevir/ombitasvir/ritonavir (15.9%) and daclatasvir+asunaprevir (12.7%). Potential DDIs remained consistently low across age groups for EBR+GZR and SOF/VEL. It is necessary to consider potential DDIs when determining a suitable DAA regimen.